NEW YORK (GenomeWeb) – Transgenomic today announced the closing of its public offering of stock and corresponding warrants that raised $6.2 million in net proceeds. 

The company offered 3,573,899 shares of its common stock and corresponding warrants to purchase 714,781 shares. The stocks and warrants were sold in combination with one warrant to purchase .20 of a share of stock for each share of stock sold. The combined price for each share and corresponding warrant was $1.95.  

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.